Vitamin E and Alzheimer’s disease: what do we know so far?
Declan Browne, Bernadette McGuinness, Jayne V Woodside, Gareth J McKayCentre for Public Health, Queen’s University Belfast, Belfast, UKAbstract: Vitamin E has been proposed as a potential clinical intervention for Alzheimer’s disease (AD) given the plausibility of its various bio...
Guardado en:
Autores principales: | Browne D, McGuinness B, Woodside JV, McKay GJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b9d2e66d8f634e0ea0e5e80bb9ca25fb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pharmacology and Pharmacokinetics of Vitamin E: Nanoformulations to Enhance Bioavailability
por: Mohd Zaffarin AS, et al.
Publicado: (2020) -
Cholesterol and vitamin E determination in broiler chickens fed cañóla oil
por: Gallardo,MA, et al.
Publicado: (2015) -
TAVI in nonagenarians, what do we know so far?
por: Pablo Díez-Villanueva, et al.
Publicado: (2021) -
Equine degenerative myeloencephalopathy: prevalence, impact, and management
por: Burns EN, et al.
Publicado: (2018) -
Identifying High-Risk NASH Patients: What We Know so Far
por: Schulz M, et al.
Publicado: (2020)